BCTX: Second Quarter Results
By John Vandermosten, CFA
NASDAQ:BCTX
READ THE FULL BCTX RESEARCH REPORT
aTyr Pharma Q4 EPS $(0.31) Misses $(0.28) Estimate
aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 34.04 percent increase over losses of $(0.47) per share from the
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell
• F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter.
A Preview Of aTyr Pharma’s Earnings
aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement.
Analysts estimate that aTyr Pharma will report an earnings per share (EPS) of $-0.28.
3 Stocks Insiders Are Buying: Univar Solutions, aTyr Pharma And More
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
ATyr Pharma Shares Spike; FDA Grants Orphan Drug Designation For Human Igg1fc-Imod Domain Of Human Hars Fusion Protein For Treatment Of Sarcoidosis
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=708419
aTyr Pharma And FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement For aTyr’s Lead Therapeutic Candidate ATYR1923
aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and FUJIFILM Diosynth Biotechnologies, a leading contract